Animal virology

Global Coronavirus Partnering Deals Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 12, 2021
Health, Infectious diseases, Animal virology, Coronavirus

b'The "Global Coronavirus Partnering 2014-2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals.\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor\'s product or technology.

Key Points: 
  • b'The "Global Coronavirus Partnering 2014-2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals.\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor\'s product or technology.
  • The chapter includes the top 25 most active Coronavirus dealmakers, together with a full listing of deals to which they are a party.
  • Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.\nChapter 6 provides a comprehensive directory of all Coronavirus partnering deals by specific Coronavirus target announced since 2014.
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\nGlobal Coronavirus Partnering 2014 to 2021 includes:\nIn Global Coronavirus Partnering 2014 to 2021, available deals and contracts are listed by:\n'

InventHelp Inventors Develop Modified Vaccination Implement for Livestock (DAE-549)

Retrieved on: 
Thursday, April 15, 2021
Medical specialties, Articles, Medicine, Animal virology, Biotechnology, Vaccination, Vaccine, Cowpox, Invention, Patent

b'PITTSBURGH, April 15, 2021 /PRNewswire/ --"We needed a more efficient way to inject vaccines into livestock," said one of two inventors, from Mankato, Minn., "so we invented the patent pending ARRAZOLO MULTIPLE VACCINATION GUN.

Key Points: 
  • b'PITTSBURGH, April 15, 2021 /PRNewswire/ --"We needed a more efficient way to inject vaccines into livestock," said one of two inventors, from Mankato, Minn., "so we invented the patent pending ARRAZOLO MULTIPLE VACCINATION GUN.
  • "\nThe invention enables two separate vaccinations to be administered to swine or poultry at the same time.
  • As a result, it saves time and effort and it can be adapted for use with a variety of vaccinations.
  • Additionally, it is producible in design variations and a prototype is available.\nThe original design was submitted to the National sales office of InventHelp.

ShareRing Joins Good Health Pass Collaborative as Contributor

Retrieved on: 
Sunday, April 11, 2021
Medical specialties, Vaccination, Medicine, Clinical medicine, Zoonoses, Animal virology, Booster dose, Cowpox, Vaccine

"The COVID-19 virus is unlikely to go away anytime soon as many scientists project it will become endemic, possibly requiring yearly boosters," he explained.

Key Points: 
  • "The COVID-19 virus is unlikely to go away anytime soon as many scientists project it will become endemic, possibly requiring yearly boosters," he explained.
  • "The need for digital health pass systems may thus likely only grow as more people get vaccinated and then possibly need subsequent booster shots.
  • The Good Health Pass Collaborative is already doing yeoman\'s work to help the world to quickly find its collective voice on a crucial technological solution.
  • "\n"We are delighted to welcome ShareRing to the Good Health Pass Collaborative," said head of advocacy and communications, Ethan Veneklasen.

Global Coronavirus Partnering Deals Market 2021: Access to Headline, Upfront, Milestone and Royalty Data

Retrieved on: 
Friday, April 16, 2021
Animal virology, Coronavirus

b'DUBLIN, April 16, 2021 /PRNewswire/ -- The "Global Coronavirus Partnering 2014-2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals.\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor\'s product or technology.

Key Points: 
  • b'DUBLIN, April 16, 2021 /PRNewswire/ -- The "Global Coronavirus Partnering 2014-2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals.\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor\'s product or technology.
  • The chapter includes the top 25 most active Coronavirus dealmakers, together with a full listing of deals to which they are a party.
  • Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.\nChapter 6 provides a comprehensive directory of all Coronavirus partnering deals by specific Coronavirus target announced since 2014.
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\nGlobal Coronavirus Partnering 2014 to 2021 includes:\nIn Global Coronavirus Partnering 2014 to 2021, available deals and contracts are listed by:\n'

OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response

Retrieved on: 
Saturday, April 10, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Virotherapy, Animal virology, Experimental cancer treatments, Chordopoxvirinae, Myxoma virus, Immunotherapy, Health sciences, Oncolytic virus, Myxoma Virus and Oncolytic Immunotherapy, OncoMyx Therapeutics

The data are the first to demonstrate that OncoMyxs multi-armed myxoma virotherapy upregulates anti-tumor immune response pathways, expresses transgenes in a dose and time-dependent manner, and produces anti-tumor efficacy in a preclinical model of cancer following intravenous (IV) or intratumoral (IT) dosing.

Key Points: 
  • The data are the first to demonstrate that OncoMyxs multi-armed myxoma virotherapy upregulates anti-tumor immune response pathways, expresses transgenes in a dose and time-dependent manner, and produces anti-tumor efficacy in a preclinical model of cancer following intravenous (IV) or intratumoral (IT) dosing.
  • One of OncoMyxs myxoma virotherapies (vMYX-hIL-12/Dec), which is multi-armed with interleukin-12 (IL-12) and decorin (Dec), upregulates interferon- (IFN-), and IFN-, and IL-12 response pathways, which are associated with anti-tumor immune response.
  • OncoMyx has specifically built multi-armed myxoma viruses with immunomodulatory proteins and payloads designed to stimulate anti-tumor immunity and deliver targeted cancer therapies.
  • OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response to better treat cancer.

Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Medicine, Clinical medicine, Immunology, Immune system, Animal virology, Zoonoses, Biotechnology, Monoclonal antibody, Severe acute respiratory syndrome coronavirus, Coronavirus, Neutralizing antibody

SAN FRANCISCO, April 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new preclinical research highlighting novel mechanisms by which SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) enters host cells and identifying how auxiliary receptors may impact the clinical efficacy of monoclonal antibodies (mAbs).

Key Points: 
  • SAN FRANCISCO, April 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new preclinical research highlighting novel mechanisms by which SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) enters host cells and identifying how auxiliary receptors may impact the clinical efficacy of monoclonal antibodies (mAbs).
  • These cells can bind to infectious SARS-CoV-2 and present the virus to another cell to establish infection in that second cell.
  • Cells that overexpress ACE-2 at levels in excess of normal cells are widely used in neutralization assays because they can be infected with high efficiency.
  • Preclinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells.

Metrex Surface Disinfectant Portfolio Secures EPA Approval for Use Against SARS-CoV-2 Virus

Retrieved on: 
Monday, April 5, 2021
Medical Supplies, Retail, Health, Other Retail, Infectious diseases, Home Goods, Specialty, Coronaviridae, Sarbecovirus, Medical specialties, Health sciences, Bat virome, Zoonoses, Animal virology, Severe acute respiratory syndrome, COVID-19, Coronavirus, Coronavir, Disinfectant

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex , as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Key Points: 
  • The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex , as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.
  • View the full release here: https://www.businesswire.com/news/home/20210405005058/en/
    The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.
  • The below Metrex surface disinfection products are effective against SARS-CoV-2, helping to give front-line workers peace of mind that our products are protecting their patients and themselves.
  • The following Metrex products have been approved by the EPA for efficacy against SARS-CoV-2 and are on the EPA list N for use against SARS-CoV-2:

LightAir IonFlow air purifier effectively reduces the infectivity of viruses that mimic coronaviruses

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Medicine, Health sciences, Animal virology, Virology, Epidemiology, Pandemics, Virus, Zoonoses, Coronavirus, Antiviral drug

This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.

Key Points: 
  • This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.
  • "We measured out various versions of pseudoviruses* that mimic the entry of different coronaviruses into cells.
  • "Personally, I find this extremely interesting, and the potential of this technology to combat virus spreading should be further investigated.
  • Not least in these times, and especially given that this technology attacks the viral entry process so viruses can no longer infect human cells."

LightAir IonFlow air purifier effectively reduces the infectivity of viruses that mimic coronaviruses

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Medicine, Health sciences, Animal virology, Virology, Epidemiology, Pandemics, Virus, Zoonoses, Coronavirus, Antiviral drug

This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.

Key Points: 
  • This evidence can now be added to a seven-year scientific study from Karolinska Institute that previously showed the technology's effectiveness against airborne viruses and how it greatly reduces the spread of infection.
  • "We measured out various versions of pseudoviruses* that mimic the entry of different coronaviruses into cells.
  • "Personally, I find this extremely interesting, and the potential of this technology to combat virus spreading should be further investigated.
  • Not least in these times, and especially given that this technology attacks the viral entry process so viruses can no longer infect human cells."

Ethris Announces Positive Scientific Review of its mRNA-Based COVID-19 Therapeutic Program Application to Bavarian BayTherapie2020 Grant Program

Retrieved on: 
Tuesday, March 30, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Occupational safety and health, Health sciences, Animal virology, COVID-19, Public health, Zoonoses, Coronavirus, Health, Articles

Ethris GmbH announced today that it has received positive review from a committee of scientific experts nominated by the Bavarian State Ministry for Economic Affairs, Regional Development and Energy, for its grant application submitted to the Bavarian Government as part of the BayTherapie2020, grant call-for-proposals.

Key Points: 
  • Ethris GmbH announced today that it has received positive review from a committee of scientific experts nominated by the Bavarian State Ministry for Economic Affairs, Regional Development and Energy, for its grant application submitted to the Bavarian Government as part of the BayTherapie2020, grant call-for-proposals.
  • By intervening early during a coronavirus infection, ETH47 is designed to stop it before the onset of severe symptoms.
  • Receiving a positive review from the scientific experts reaffirms the potential of Ethris science and RNA technology platform.
  • The positive review of the application is of course a great recognition for Ethris, and I look forward to the companys progress as it develops a novel therapeutic for COVID-19.